← 產業報告目錄
Leukemia Inhibitory Factor (LIF) Market Size, Share & Trends Analysis Report By Product type (LIF Antibodies, Recombinant LIF, LIF Receptor Agonists/Antagonists), By Application (Cancer Treatment, Neurological Disorders, Stem Cell Research, Fertility Treatment, Others), By End-User (Hospitals, Biotechnology Companies, Research Institutes, Others), by Region, And by Segment Forecasts, 2025-2034.
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-16頁數 180報告編號 INSIGHTACE-5e502561de
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
In 2024, the Leukemia Inhibitory Factor (LIF) Market worldwide was assessed at USD 1.29 Bn. Analysts project it will surge to USD 3.02 Bn by 2034, at a CAGR of 9.0% spanning 2025 to 2034.
Leukemia Inhibitory Factor (LIF) covers reshaping how healthcare entities approach this space.
Growth is bolstered by a convergence of factors: rising awareness among end users, continuous product innovation, and the surging emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, bolstered by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Leukemia Inhibitory Factor (LIF) Market Snapshot
Chapter 4. Global Leukemia Inhibitory Factor (LIF) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Leukemia Inhibitory Factor (LIF) Market Industry Trends
4.10. Global Leukemia Inhibitory Factor (LIF) Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Leukemia Inhibitory Factor (LIF) Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share by Product Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product Type:
5.2.1. Recombinant LIF
5.2.2. LIF Antibodies
5.2.3. LIF Receptor Agonists/Antagonists
Chapter 6. Leukemia Inhibitory Factor (LIF) Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Cancer Treatment
6.2.2. Stem Cell Research
6.2.3. Neurological Disorders
6.2.4. Fertility Treatment
6.2.5. Others
Chapter 7. Leukemia Inhibitory Factor (LIF) Market Segmentation 3: By End-User, Estimates & Trend Analysis
7.1. Market Share by End-User, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User:
7.2.1. Hospitals
7.2.2. Biotechnology Companies
7.2.3. Others
Chapter 8. Leukemia Inhibitory Factor (LIF) Market Segmentation 5: Regional Estimates & Trend Analysis
8.1. Global Leukemia Inhibitory Factor (LIF) Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
8.2.3. North America Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.2.4. North America Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
8.3. Europe
8.3.1. Europe Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
8.3.3. Europe Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.3.4. Europe Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
8.4.3. Asia Pacific Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.4.4. Asia Pacific Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
8.5. Latin America
8.5.1. Latin America Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
8.5.3. Latin America Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.5.4. Latin America Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
8.6.3. Middle East & Africa Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.6.4. Middle East & Africa Leukemia Inhibitory Factor (LIF) Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Bristol Myers Squibb
9.2.1.1. Business Overview
9.2.1.2. Key Product Type/Service Overview
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. InVitria
9.2.3. Johnson & Johnson Private Limited
9.2.4. Gilead Sciences Inc.
9.2.5. Sanofi S.A.
9.2.6. Novartis AG
9.2.7. Roche
9.2.8. Amgen Inc.
9.2.9. Merck KGaA
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們